Date | Issuer | Insider | Transaction | Amount | New Balance ⓘ
The balance of securities held by registered holder at the time of the transaction. Insiders may direct multiple registered holders and hold multiple security types.
|
|
---|---|---|---|---|---|---|
Filed 2019-12-13 08:45 Tx date 2019-12-12 |
$NVLN
Novelion Therapeutics Inc. |
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$700.00
+1,000 vol $0.70 each |
3,909,207 | |
Filed 2019-12-13 08:45 Tx date 2019-12-11 |
$NVLN
Novelion Therapeutics Inc. |
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$27.60
+40 vol $0.69 each |
3,908,207 | |
Filed 2019-12-13 08:44 Tx date 2019-12-10 |
$NVLN
Novelion Therapeutics Inc. |
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,597
+5,202 vol $0.69 each |
3,908,167 | |
Filed 2019-12-09 17:50 Tx date 2019-12-09 |
$NVLN
Novelion Therapeutics Inc. |
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,150
+4,500 vol $0.70 each |
3,902,965 | |
Filed 2019-12-09 17:46 Tx date 2019-12-09 |
$NVLN
Novelion Therapeutics Inc. |
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,150
+4,500 vol $0.70 each |
||
Filed 2019-12-09 17:45 Tx date 2019-12-06 |
$NVLN
Novelion Therapeutics Inc. |
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$28.00
+40 vol $0.70 each |
3,898,465 | |
Filed 2019-12-09 17:44 Tx date 2019-12-05 |
$NVLN
Novelion Therapeutics Inc. |
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,611
+5,160 vol $0.70 each |
3,898,425 | |
Filed 2019-12-09 17:40 Tx date 2019-12-09 |
$NVLN
Novelion Therapeutics Inc. |
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,150
+4,500 vol $0.70 each |
||
Filed 2019-12-09 17:39 Tx date 2019-12-06 |
$NVLN
Novelion Therapeutics Inc. |
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$28.00
+40 vol $0.70 each |
||
Filed 2019-12-09 17:39 Tx date 2019-12-05 |
$NVLN
Novelion Therapeutics Inc. |
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,611
+5,160 vol $0.70 each |
||
Filed 2019-11-26 18:19 Tx date 2019-11-22 |
$NVLN
Novelion Therapeutics Inc. |
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$67,033
+89,845 vol $0.75 each |
3,893,265 | |
Filed 2019-10-16 19:54 Tx date 2019-10-11 |
$NVLN
Novelion Therapeutics Inc. |
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$64,900
+100,000 vol $0.65 each |
3,803,420 | |
Filed 2019-10-16 19:52 Tx date 2019-09-23 |
$NVLN
Novelion Therapeutics Inc. |
Stonepine Capital Management, LLC
3 - 10% Security Holder of Issuer
Holder: Stonepine Capital, LP (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
3,703,420 | ||
Filed 2019-09-27 16:24 Tx date 2019-09-24 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-1,282.88
-1,688 vol $0.76 each |
15,391 | |
Filed 2019-09-27 16:18 Tx date 2019-09-24 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$4,357
+5,733 vol $0.76 each |
17,079 | |
Filed 2019-09-27 16:18 Tx date 2019-09-24 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-4,357.08
-5,733 vol $0.76 each |
996 | |
Filed 2019-09-27 16:16 Tx date 2019-09-24 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$10,133
+13,333 vol $0.76 each |
14,111 | |
Filed 2019-09-27 16:16 Tx date 2019-09-24 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-10,133.08
-13,333 vol $0.76 each |
0 | |
Filed 2019-09-27 16:15 Tx date 2019-09-24 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$10,133
+13,333 vol $0.76 each |
||
Filed 2019-09-27 16:14 Tx date 2019-09-24 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-10,133.08
-13,333 vol $0.76 each |
||
Filed 2019-09-27 16:14 Tx date 2019-09-24 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-2,983.76
-3,926 vol $0.76 each |
778 | |
Filed 2019-09-27 16:13 Tx date 2019-09-24 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$10,133
+13,333 vol $0.76 each |
||
Filed 2019-09-27 16:13 Tx date 2019-09-24 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-10,133.08
-13,333 vol $0.76 each |
||
Filed 2019-05-14 11:35 Tx date 2019-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-93.94
-77 vol $1.22 each |
570 | |
Filed 2019-05-14 11:35 Tx date 2019-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$333.06
+273 vol $1.22 each |
647 | |
Filed 2019-05-14 11:34 Tx date 2019-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-333.06
-273 vol $1.22 each |
47,980 | |
Filed 2019-05-14 11:30 Tx date 2019-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-189.10
-155 vol $1.22 each |
1,162 | |
Filed 2019-05-14 11:30 Tx date 2019-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$666.12
+546 vol $1.22 each |
1,317 | |
Filed 2019-05-14 11:28 Tx date 2019-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-666.12
-546 vol $1.22 each |
20,560 | |
Filed 2019-05-14 11:18 Tx date 2019-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-258.64
-212 vol $1.22 each |
3,683 | |
Filed 2019-05-14 11:18 Tx date 2019-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$880.84
+722 vol $1.22 each |
3,895 | |
Filed 2019-05-14 11:16 Tx date 2019-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-880.84
-722 vol $1.22 each |
47,982 | |
Filed 2019-03-19 Tx date 2019-03-15 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-1,254.96
-996 vol $1.26 each |
11,346 | |
Filed 2019-03-19 Tx date 2019-03-15 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$2,357
+1,871 vol $1.26 each |
12,342 | |
Filed 2019-03-19 Tx date 2019-03-15 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-2,357.46
-1,871 vol $1.26 each |
6,729 | |
Filed 2018-12-27 Tx date 2018-12-26 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-81,446.908
-83,245 vol $0.98 each |
1,863,709 | |
Filed 2018-12-27 Tx date 2018-12-24 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-392.00
-400 vol $0.98 each |
1,948,154 | |
Filed 2018-12-27 Tx date 2018-12-26 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-81,446.908
-83,245 vol $0.98 each |
1,863,709 | |
Filed 2018-12-27 Tx date 2018-12-26 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,119
-1,200 vol $0.93 each |
1,946,954 | |
Filed 2018-12-27 Tx date 2018-12-24 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-392.00
-400 vol $0.98 each |
1,948,154 | |
Filed 2018-12-27 Tx date 2018-12-26 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,119
-1,200 vol $0.93 each |
1,946,954 | |
Filed 2018-12-27 Tx date 2018-12-26 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-81,446.908
-83,245 vol $0.98 each |
1,863,709 | |
Filed 2018-12-27 Tx date 2018-12-24 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-392.00
-400 vol $0.98 each |
1,948,154 | |
Filed 2018-12-27 Tx date 2018-12-26 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,119
-1,200 vol $0.93 each |
1,946,954 | |
Filed 2018-12-10 Tx date 2018-12-06 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-14,400
-11,250 vol $1.28 each |
8,600 | |
Filed 2018-12-10 Tx date 2018-12-06 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$14,400
+11,250 vol $1.28 each |
13,784 | |
Filed 2018-12-10 Tx date 2018-12-06 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-4,240.64
-3,313 vol $1.28 each |
10,471 | |
Filed 2018-11-28 Tx date 2018-11-27 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$6,132
+6,667 vol $0.92 each |
||
Filed 2018-11-28 Tx date 2018-11-27 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$1,805
+1,963 vol $0.92 each |
||
Filed 2018-11-28 Tx date 2018-11-27 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$6,132
+6,667 vol $0.92 each |
6,667 | |
Filed 2018-11-28 Tx date 2018-11-27 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$1,805
+1,963 vol $0.92 each |
||
Filed 2018-11-28 Tx date 2017-12-04 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-11-28 Tx date 2018-11-27 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$6,132
+6,667 vol $0.92 each |
||
Filed 2018-11-28 Tx date 2018-11-27 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-6,132.9733
-6,667 vol $0.92 each |
13,333 | |
Filed 2018-11-28 Tx date 2018-11-27 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-1,805.7637
-1,963 vol $0.92 each |
4,704 | |
Filed 2018-11-05 Tx date 2018-09-17 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-386.12
-98 vol $3.94 each |
||
Filed 2018-11-05 Tx date 2018-09-17 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-386.12
-98 vol $3.94 each |
||
Filed 2018-11-05 Tx date 2018-05-15 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-622.50
-150 vol $4.15 each |
||
Filed 2018-11-05 Tx date 2018-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-1,371.72
-322 vol $4.26 each |
||
Filed 2018-11-05 Tx date 2017-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-11-05 Tx date 2018-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$28,840
+32,149 vol $0.90 each |
||
Filed 2018-11-05 Tx date 2018-05-15 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-622.50
-150 vol $4.15 each |
||
Filed 2018-11-05 Tx date 2018-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-28,840.8679
-32,149 vol $0.90 each |
||
Filed 2018-11-05 Tx date 2018-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$97,933
+109,167 vol $0.90 each |
109,167 | |
Filed 2018-11-05 Tx date 2018-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-97,933.7157
-109,167 vol $0.90 each |
33,333 | |
Filed 2018-11-05 Tx date 2018-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-28,840.8679
-32,149 vol $0.90 each |
||
Filed 2018-11-05 Tx date 2018-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-1,371.72
-322 vol $4.26 each |
||
Filed 2018-11-05 Tx date 2018-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-28,840.8679
-32,149 vol $0.90 each |
77,018 | |
Filed 2018-11-05 Tx date 2018-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$28,840
+32,149 vol $0.90 each |
||
Filed 2018-09-18 Tx date 2018-09-17 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
$-1,323.84
-336 vol $3.94 each |
48,704 | |
Filed 2018-09-18 Tx date 2018-09-17 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
$1,323
+336 vol $3.94 each |
3,271 | |
Filed 2018-09-18 Tx date 2018-09-17 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-386.12
-98 vol $3.94 each |
3,173 | |
Filed 2018-08-27 Tx date 2018-08-22 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+50,000 vol |
136,665 | |
Filed 2018-08-14 Tx date 2018-08-09 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$33,300
+10,000 vol $3.33 each |
19,600 | |
Filed 2018-08-14 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Assignment Agreement
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-08-14 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Assignment Agreement
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-08-14 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Assignment Agreement
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-08-14 Tx date 2018-08-09 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Assignment Agreement
70 - Acquisition or disposition (writing) of third party derivative
|
$-3.33
-1 vol $3.33 each |
0 | |
Filed 2018-08-14 Tx date 2018-08-09 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Assignment Agreement
70 - Acquisition or disposition (writing) of third party derivative
|
$3.33
+1 vol $3.33 each |
1 | |
Filed 2018-08-14 Tx date 2018-08-09 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Assignment Agreement
70 - Acquisition or disposition (writing) of third party derivative
|
$3.33
+1 vol $3.33 each |
2 | |
Filed 2018-08-14 Tx date 2018-08-09 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
|
Assignment Agreement
70 - Acquisition or disposition (writing) of third party derivative
|
$3.33
+1 vol $3.33 each |
2 | |
Filed 2018-08-13 Tx date 2018-08-09 |
$NVLN
Novelion Therapeutics Inc. |
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+10,000 vol |
29,600 | |
Filed 2018-08-13 Tx date 2018-08-09 |
$NVLN
Novelion Therapeutics Inc. |
Stern, Donald
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+10,000 vol |
19,600 | |
Filed 2018-08-13 Tx date 2018-08-09 |
$NVLN
Novelion Therapeutics Inc. |
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+10,000 vol |
29,600 | |
Filed 2018-08-13 Tx date 2018-08-09 |
$NVLN
Novelion Therapeutics Inc. |
Orloff, John
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+10,000 vol |
185,620 | |
Filed 2018-08-13 Tx date 2018-08-09 |
$NVLN
Novelion Therapeutics Inc. |
DiPaolo, Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+10,000 vol |
19,600 | |
Filed 2018-08-13 Tx date 2018-08-09 |
$NVLN
Novelion Therapeutics Inc. |
Corrigan, Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+50,000 vol |
59,600 | |
Filed 2018-08-13 Tx date 2018-08-09 |
$NVLN
Novelion Therapeutics Inc. |
Bruhn, Suzanne Louise
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+10,000 vol |
19,600 | |
Filed 2018-07-16 Tx date 2018-03-13 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Global Growth & Income Portfolio (Control or Direction)
|
Convertible Notes
11 - Acquisition or disposition carried out privately
|
$
+$750,000 vol $77.00 each |
$35,916,800 | |
Filed 2018-07-16 Tx date 2017-11-07 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Global Growth & Income Portfolio (Control or Direction)
|
Convertible Notes
00 - Opening Balance-Initial SEDI Report
|
$35,166,800 | ||
Filed 2018-07-16 Tx date 2017-11-07 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
|
Convertible Notes
00 - Opening Balance-Initial SEDI Report
|
$4,000,000 | ||
Filed 2018-07-16 Tx date 2017-11-07 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
|
Convertible Notes
00 - Opening Balance-Initial SEDI Report
|
$12,475,200 | ||
Filed 2018-07-16 Tx date 2018-01-02 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$5,811
+1,833 vol $3.17 each |
1,350,323 | |
Filed 2018-07-16 Tx date 2017-12-06 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$527,544
+150,727 vol $3.50 each |
1,348,490 | |
Filed 2018-07-16 Tx date 2017-12-05 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$50,561
+14,446 vol $3.50 each |
1,197,763 | |
Filed 2018-07-16 Tx date 2017-12-05 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$386,387
+104,840 vol $3.69 each |
1,183,317 | |
Filed 2018-07-16 Tx date 2017-12-01 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,334
+883 vol $3.78 each |
1,078,477 | |
Filed 2018-07-16 Tx date 2017-12-01 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$16,355
+4,389 vol $3.73 each |
1,077,594 | |
Filed 2018-07-16 Tx date 2017-11-15 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$33,733
+7,681 vol $4.39 each |
1,073,205 | |
Filed 2018-07-16 Tx date 2017-11-14 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$36,599
+8,328 vol $4.39 each |
1,065,524 | |
Filed 2018-07-16 Tx date 2017-11-13 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$784.83
+181 vol $4.34 each |
1,057,196 | |
Filed 2018-07-16 Tx date 2017-11-10 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$17,094
+3,949 vol $4.33 each |
1,057,015 | |
Filed 2018-07-16 Tx date 2017-11-09 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,091
+719 vol $4.30 each |
1,053,066 | |
Filed 2018-07-16 Tx date 2017-11-07 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Portfolio (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
1,052,347 | ||
Filed 2018-07-16 Tx date 2018-01-02 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$4,175
+1,317 vol $3.17 each |
844,740 | |
Filed 2018-07-16 Tx date 2017-12-06 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$337,939
+96,554 vol $3.50 each |
843,423 | |
Filed 2018-07-16 Tx date 2017-12-05 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$247,518
+67,160 vol $3.69 each |
746,869 | |
Filed 2018-07-16 Tx date 2017-12-05 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$32,389
+9,254 vol $3.50 each |
679,709 | |
Filed 2018-07-16 Tx date 2017-12-01 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$10,474
+2,811 vol $3.73 each |
670,455 | |
Filed 2018-07-16 Tx date 2017-12-01 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$2,137
+566 vol $3.78 each |
667,644 | |
Filed 2018-07-16 Tx date 2017-11-15 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$18,375
+4,184 vol $4.39 each |
667,078 | |
Filed 2018-07-16 Tx date 2017-11-14 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$19,943
+4,538 vol $4.39 each |
662,894 | |
Filed 2018-07-16 Tx date 2017-11-13 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$429.27
+99 vol $4.34 each |
658,356 | |
Filed 2018-07-16 Tx date 2017-11-10 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$9,311
+2,151 vol $4.33 each |
658,257 | |
Filed 2018-07-16 Tx date 2017-11-09 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
|
Common Shares
10 - Acquisition or disposition in the public market
|
$1,681
+391 vol $4.30 each |
656,106 | |
Filed 2018-07-16 Tx date 2017-11-07 |
$NVLN
Novelion Therapeutics Inc. |
EdgePoint Investment Group Inc.
3 - 10% Security Holder of Issuer
Holder: EdgePoint Canadian Growth & Income Portfolio (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
655,715 | ||
Filed 2018-05-17 Tx date 2018-05-15 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
-150 vol |
2,935 | |
Filed 2018-05-17 Tx date 2018-05-15 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
-512 vol |
49,040 | |
Filed 2018-05-17 Tx date 2018-05-15 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+512 vol |
3,085 | |
Filed 2018-05-11 Tx date 2018-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
-547 vol |
21,106 | |
Filed 2018-05-11 Tx date 2018-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-685.86
-161 vol $4.26 each |
771 | |
Filed 2018-05-11 Tx date 2018-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+547 vol |
932 | |
Filed 2018-05-11 Tx date 2018-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
-748 vol |
49,552 | |
Filed 2018-05-11 Tx date 2018-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
-349 vol |
50,300 | |
Filed 2018-05-11 Tx date 2018-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-937.20
-220 vol $4.26 each |
2,573 | |
Filed 2018-05-11 Tx date 2018-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+748 vol |
2,793 | |
Filed 2018-05-11 Tx date 2018-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-434.52
-102 vol $4.26 each |
2,045 | |
Filed 2018-05-11 Tx date 2018-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+349 vol |
2,147 | |
Filed 2018-05-11 Tx date 2018-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-340.80
-80 vol $4.26 each |
374 | |
Filed 2018-05-11 Tx date 2018-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+273 vol |
454 | |
Filed 2018-05-11 Tx date 2018-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
-273 vol |
48,253 | |
Filed 2018-04-03 Tx date 2018-04-01 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
36 - Conversion or exchange
|
-177 vol |
50,649 | |
Filed 2018-04-03 Tx date 2018-04-01 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-182.00
-52 vol $3.50 each |
1,798 | |
Filed 2018-04-03 Tx date 2018-04-01 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$182.00
+52 vol $3.50 each |
||
Filed 2018-04-03 Tx date 2018-04-01 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$182.00
+52 vol $3.50 each |
||
Filed 2018-04-03 Tx date 2018-04-01 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
36 - Conversion or exchange
|
+177 vol |
1,850 | |
Filed 2018-03-26 Tx date 2018-03-15 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
56 - Grant of rights
|
+8,600 vol |
19,850 | |
Filed 2018-03-26 Tx date 2018-03-15 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+40,000 vol |
86,665 | |
Filed 2018-03-16 Tx date 2018-03-15 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Warrants
53 - Grant of warrants
|
+909,296 vol |
909,296 | |
Filed 2018-03-16 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-03-16 Tx date 2018-03-15 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants
53 - Grant of warrants
|
+909,296 vol |
909,296 | |
Filed 2018-03-16 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-03-16 Tx date 2018-03-15 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
|
Warrants
53 - Grant of warrants
|
+909,296 vol |
909,296 | |
Filed 2018-03-16 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
|
Warrants
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2018-02-14 Tx date 2018-02-12 |
$NVLN
Novelion Therapeutics Inc. |
Stewart, Murray
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+45,000 vol |
245,000 | |
Filed 2018-02-14 Tx date 2018-02-12 |
$NVLN
Novelion Therapeutics Inc. |
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+25,000 vol |
66,740 | |
Filed 2018-02-14 Tx date 2018-02-12 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+45,000 vol |
217,400 | |
Filed 2018-02-14 Tx date 2018-02-12 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+25,000 vol |
122,400 | |
Filed 2018-02-14 Tx date 2018-02-12 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+25,000 vol |
||
Filed 2018-02-14 Tx date 2018-02-12 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+25,000 vol |
||
Filed 2017-12-11 Tx date 2017-12-06 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
57 - Exercise of rights
|
-3,750 vol |
11,250 | |
Filed 2017-12-11 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
37 - Stock split or consolidation
|
-60,000 vol |
15,000 | |
Filed 2017-12-11 Tx date 2017-12-06 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-4,049.28
-1,216 vol $3.33 each |
2,534 | |
Filed 2017-12-11 Tx date 2017-12-06 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
57 - Exercise of rights
|
+3,750 vol |
3,750 | |
Filed 2017-12-11 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-12-07 Tx date 2017-12-04 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
56 - Grant of rights
|
+20,000 vol |
20,000 | |
Filed 2017-12-07 Tx date 2017-12-04 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-12-07 Tx date 2017-12-04 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+100,000 vol |
100,000 | |
Filed 2017-12-07 Tx date 2017-12-04 |
$NVLN
Novelion Therapeutics Inc. |
Price, Michael
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-11-30 Tx date 2017-11-27 |
$NVLN
Novelion Therapeutics Inc. |
Stewart, Murray
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
|
50,000 | ||
Filed 2017-11-30 Tx date 2017-11-27 |
$NVLN
Novelion Therapeutics Inc. |
Stewart, Murray
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
200,000 | ||
Filed 2017-11-03 Tx date 2017-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
56 - Grant of rights
|
+92,500 vol |
142,500 | |
Filed 2017-11-03 Tx date 2017-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
56 - Grant of rights
|
+50,000 vol |
50,000 | |
Filed 2017-11-03 Tx date 2017-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-11-03 Tx date 2017-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+135,000 vol |
135,000 | |
Filed 2017-11-03 Tx date 2017-11-01 |
$NVLN
Novelion Therapeutics Inc. |
Hackman, Jeffrey
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-10-10 Tx date 2017-10-06 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+75,000 vol |
172,400 | |
Filed 2017-10-05 Tx date 2017-10-02 |
$NVLN
Novelion Therapeutics Inc. |
Bruhn, Suzanne Louise
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+9,600 vol |
9,600 | |
Filed 2017-10-05 Tx date 2017-10-01 |
$NVLN
Novelion Therapeutics Inc. |
Bruhn, Suzanne Louise
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-09-19 Tx date 2017-09-17 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
36 - Conversion or exchange
|
-337 vol |
50,826 | |
Filed 2017-09-19 Tx date 2017-09-17 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-771.72
-109 vol $7.08 each |
1,673 | |
Filed 2017-09-19 Tx date 2017-09-17 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
36 - Conversion or exchange
|
+337 vol |
1,782 | |
Filed 2017-08-02 Tx date 2017-08-02 |
$NVLN
Novelion Therapeutics Inc. |
DiPaolo, Mark
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
9,600 | ||
Filed 2017-07-05 Tx date 2017-07-03 |
$NVLN
Novelion Therapeutics Inc. |
Orloff, John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+9,600 vol |
175,620 | |
Filed 2017-06-14 Tx date 2017-06-12 |
$NVLN
Novelion Therapeutics Inc. |
Stern, Donald
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$22,750
+2,500 vol $9.10 each |
2,500 | |
Filed 2017-06-14 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Stern, Donald
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-05-17 Tx date 2017-05-15 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
36 - Conversion or exchange
|
-717 vol |
51,163 | |
Filed 2017-05-17 Tx date 2017-05-15 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-2,081.04
-232 vol $8.97 each |
1,445 | |
Filed 2017-05-17 Tx date 2017-05-15 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$3,230
+361 vol $8.95 each |
242,433 | |
Filed 2017-05-17 Tx date 2017-05-15 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
36 - Conversion or exchange
|
+717 vol |
1,677 | |
Filed 2017-05-11 Tx date 2017-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
36 - Conversion or exchange
|
+547 vol |
547 | |
Filed 2017-05-11 Tx date 2017-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
36 - Conversion or exchange
|
-6,632 vol |
184,924 | |
Filed 2017-05-11 Tx date 2017-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
36 - Conversion or exchange
|
+6,632 vol |
6,632 | |
Filed 2017-05-11 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-05-11 Tx date 2017-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
36 - Conversion or exchange
|
-2,393 vol |
86,546 | |
Filed 2017-05-11 Tx date 2017-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-6,688.20
-710 vol $9.42 each |
1,683 | |
Filed 2017-05-11 Tx date 2017-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
36 - Conversion or exchange
|
-547 vol |
21,653 | |
Filed 2017-05-11 Tx date 2017-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-1,526.04
-162 vol $9.42 each |
385 | |
Filed 2017-05-11 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-05-11 Tx date 2017-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
36 - Conversion or exchange
|
-375 vol |
51,880 | |
Filed 2017-05-11 Tx date 2017-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
36 - Conversion or exchange
|
-349 vol |
52,255 | |
Filed 2017-05-11 Tx date 2017-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-1,139.82
-121 vol $9.42 each |
960 | |
Filed 2017-05-11 Tx date 2017-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
36 - Conversion or exchange
|
+375 vol |
1,081 | |
Filed 2017-05-11 Tx date 2017-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
36 - Conversion or exchange
|
+349 vol |
819 | |
Filed 2017-05-11 Tx date 2017-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
36 - Conversion or exchange
|
-274 vol |
48,526 | |
Filed 2017-05-11 Tx date 2017-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-876.06
-93 vol $9.42 each |
181 | |
Filed 2017-05-11 Tx date 2017-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-21,176.16
-2,248 vol $9.42 each |
4,384 | |
Filed 2017-05-11 Tx date 2017-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
36 - Conversion or exchange
|
+274 vol |
274 | |
Filed 2017-05-11 Tx date 2017-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-1,064.46
-113 vol $9.42 each |
706 | |
Filed 2017-05-11 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-05-11 Tx date 2017-05-09 |
$NVLN
Novelion Therapeutics Inc. |
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
36 - Conversion or exchange
|
+2,393 vol |
2,393 | |
Filed 2017-05-11 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-05-03 Tx date 2017-05-01 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+20,000 vol |
46,665 | |
Filed 2017-04-06 Tx date 2017-04-01 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
11 - Acquisition or disposition carried out privately
|
$-612.18
-57 vol $10.74 each |
470 | |
Filed 2017-04-06 Tx date 2017-04-01 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
36 - Conversion or exchange
|
-178 vol |
52,604 | |
Filed 2017-04-06 Tx date 2017-04-01 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
36 - Conversion or exchange
|
+178 vol |
527 | |
Filed 2017-04-05 Tx date 2017-03-30 |
$NVLN
Novelion Therapeutics Inc. |
Corrigan, Mark
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-04-05 Tx date 2017-03-30 |
$NVLN
Novelion Therapeutics Inc. |
Corrigan, Mark
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
9,600 | ||
Filed 2017-04-05 Tx date 2017-03-30 |
$NVLN
Novelion Therapeutics Inc. |
Corrigan, Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+9,600 vol |
||
Filed 2017-04-05 Tx date 2017-03-30 |
$NVLN
Novelion Therapeutics Inc. |
Corrigan, Mark
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-04-05 Tx date 2017-03-30 |
$NVLN
Novelion Therapeutics Inc. |
Corrigan, Mark
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+9,600 vol |
||
Filed 2017-02-03 Tx date 2017-01-27 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Restricted Stock Unit
36 - Conversion or exchange
|
-456 vol |
||
Filed 2017-02-03 Tx date 2017-01-27 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,388.24
-148 vol $9.38 each |
||
Filed 2017-02-03 Tx date 2017-01-27 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,388.24
-148 vol $9.38 each |
||
Filed 2017-02-03 Tx date 2017-01-27 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Restricted Stock Unit
36 - Conversion or exchange
|
-456 vol |
||
Filed 2017-01-31 Tx date 2017-01-27 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Restricted Stock Unit
36 - Conversion or exchange
|
-456 vol |
1,367 | |
Filed 2017-01-31 Tx date 2017-01-27 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Common Shares
36 - Conversion or exchange
|
+456 vol |
1,048 | |
Filed 2017-01-31 Tx date 2017-01-27 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Common Shares
10 - Acquisition or disposition in the public market
|
$-1,388.24
-148 vol $9.38 each |
900 | |
Filed 2017-01-18 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Kevin Kotler (Control or Direction)
|
Options
50 - Grant of options
|
$83,040
+9,600 vol $8.65 each |
||
Filed 2017-01-18 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Kevin Kotler (Control or Direction)
|
Options
50 - Grant of options
|
$83,040
+9,600 vol $8.65 each |
||
Filed 2017-01-18 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Kevin Kotler (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-01-18 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Kevin Kotler (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-01-18 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Kevin Kotler (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-01-18 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Kevin Kotler (Control or Direction)
|
Options
50 - Grant of options
|
$83,040
+9,600 vol $8.65 each |
||
Filed 2017-01-17 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Assignment Agreement
70 - Acquisition or disposition (writing) of third party derivative
|
$8.65
+1 vol $8.65 each |
1 | |
Filed 2017-01-17 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Assignment Agreement
70 - Acquisition or disposition (writing) of third party derivative
|
$-8.65
-1 vol $8.65 each |
0 | |
Filed 2017-01-17 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
|
Assignment Agreement
70 - Acquisition or disposition (writing) of third party derivative
|
$8.65
+1 vol $8.65 each |
1 | |
Filed 2017-01-17 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Assignment Agreement
70 - Acquisition or disposition (writing) of third party derivative
|
$8.65
+1 vol $8.65 each |
1 | |
Filed 2017-01-13 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
|
Assignment Agreement
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-01-13 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
|
Assignment Agreement
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-01-13 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
|
Assignment Agreement
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-01-13 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Assignment Agreement
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-01-13 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Assignment Agreement
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2017-01-13 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
|
Assignment Agreement
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-29 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
00 - Opening Balance-Initial SEDI Report
|
8,110,740 | ||
Filed 2016-12-29 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
|
Common Shares
37 - Stock split or consolidation
|
-7,794,216 vol |
1,948,554 | |
Filed 2016-12-29 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
|
Warrants Class Action Lawsuit Warrant
00 - Opening Balance-Initial SEDI Report
|
8,110,740 | ||
Filed 2016-12-29 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
|
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation
|
-6,488,592 vol |
1,622,148 | |
Filed 2016-12-29 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
|
Warrants DOJ/SEC Matter Warrant
00 - Opening Balance-Initial SEDI Report
|
8,110,740 | ||
Filed 2016-12-29 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
|
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation
|
-6,488,592 vol |
1,622,148 | |
Filed 2016-12-29 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
|
Warrants Fully Paid Warrant
00 - Opening Balance-Initial SEDI Report
|
2,840,909 | ||
Filed 2016-12-29 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
|
Warrants Fully Paid Warrant
37 - Stock split or consolidation
|
-2,272,728 vol |
568,181 | |
Filed 2016-12-29 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-7,794,216 vol |
1,948,554 | |
Filed 2016-12-29 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation
|
-6,488,592 vol |
1,622,148 | |
Filed 2016-12-29 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
00 - Opening Balance-Initial SEDI Report
|
8,110,740 | ||
Filed 2016-12-29 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation
|
-6,488,592 vol |
1,622,148 | |
Filed 2016-12-29 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants Fully Paid Warrant
00 - Opening Balance-Initial SEDI Report
|
2,840,909 | ||
Filed 2016-12-29 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Warrants Fully Paid Warrant
37 - Stock split or consolidation
|
-2,272,728 vol |
568,181 | |
Filed 2016-12-27 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
VanLent, Anne
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
VanLent, Anne
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-3,282 vol |
820 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation
|
-29,600 vol |
7,400 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation
|
-29,600 vol |
||
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation
|
-29,600 vol |
7,400 | |
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
VanLent, Anne
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+9,600 vol |
9,600 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation
|
-29,600 vol |
||
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
|
Rights Phantom Stock Units
37 - Stock split or consolidation
|
-22,720 vol |
5,680 | |
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+9,600 vol |
19,600 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
$-57,200
-40,000 vol $1.43 each |
10,000 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-29,600 vol |
7,400 | |
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
56 - Grant of rights
|
+171,660 vol |
191,556 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
37 - Stock split or consolidation
|
-79,587 vol |
19,896 | |
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+323,520 vol |
323,520 | |
Filed 2016-12-27 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Stern, Donald
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+9,600 vol |
9,600 | |
Filed 2016-12-27 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Stern, Donald
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Restricted Stock Unit
37 - Stock split or consolidation
|
-7,292 vol |
1,823 | |
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+9,600 vol |
9,600 | |
Filed 2016-12-27 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-2,371 vol |
592 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation
|
-29,600 vol |
7,400 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation
|
-29,600 vol |
||
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation
|
-29,600 vol |
7,400 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation
|
-29,600 vol |
||
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
|
Rights Phantom Stock Units
37 - Stock split or consolidation
|
-22,720 vol |
5,680 | |
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+9,600 vol |
19,600 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
$-57,200
-40,000 vol $1.43 each |
10,000 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-29,600 vol |
7,400 | |
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Plutzky, Jorge
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+9,600 vol |
9,600 | |
Filed 2016-12-27 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Plutzky, Jorge
4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
56 - Grant of rights
|
+81,760 vol |
88,939 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
37 - Stock split or consolidation
|
-28,717 vol |
7,179 | |
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+166,020 vol |
166,020 | |
Filed 2016-12-27 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Orloff, John
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
56 - Grant of rights
|
+81,760 vol |
81,760 | |
Filed 2016-12-27 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Orloff, John
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Orloff, John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+166,020 vol |
166,020 | |
Filed 2016-12-27 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Orloff, John
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Menes, Remi
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
56 - Grant of rights
|
+47,980 vol |
47,980 | |
Filed 2016-12-27 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Menes, Remi
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Menes, Remi
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+97,400 vol |
97,400 | |
Filed 2016-12-27 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Menes, Remi
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
56 - Grant of rights
|
+20,560 vol |
22,200 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
37 - Stock split or consolidation
|
-6,564 vol |
1,640 | |
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+41,740 vol |
41,740 | |
Filed 2016-12-27 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Warrants Fully Paid Warrant
37 - Stock split or consolidation
|
-2,272,728 vol |
568,181 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation
|
-6,488,592 vol |
1,622,148 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation
|
-6,488,592 vol |
||
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation
|
-6,488,592 vol |
1,622,148 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation
|
-6,488,592 vol |
||
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+9,600 vol |
||
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+9,600 vol |
||
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
$83,040
+9,600 vol $8.65 each |
9,600 | |
Filed 2016-12-27 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Common Shares
37 - Stock split or consolidation
|
-7,794,216 vol |
1,948,554 | |
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
56 - Grant of rights
|
+47,980 vol |
52,782 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
37 - Stock split or consolidation
|
-19,210 vol |
4,802 | |
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+97,400 vol |
97,400 | |
Filed 2016-12-27 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-1,398 vol |
349 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation
|
-62,800 vol |
15,700 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation
|
-62,800 vol |
||
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation
|
-62,800 vol |
15,700 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation
|
-62,800 vol |
||
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
|
Rights Phantom Stock Units
37 - Stock split or consolidation
|
-22,720 vol |
5,680 | |
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+9,600 vol |
87,600 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
$-72,000
-40,000 vol $1.80 each |
78,000 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
$-286,000
-200,000 vol $1.43 each |
118,000 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
$-321,840
-72,000 vol $4.47 each |
318,000 | |
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
56 - Grant of rights
|
+47,980 vol |
48,800 | |
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+97,400 vol |
97,400 | |
Filed 2016-12-27 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Kevin Kotler (Control or Direction)
|
Options
50 - Grant of options
|
$83,040
+9,600 vol $8.65 each |
9,600 | |
Filed 2016-12-27 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Kevin Kotler (Control or Direction)
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
|
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation
|
-369,183 vol |
92,295 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
|
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation
|
-369,183 vol |
||
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation
|
-968,291 vol |
242,072 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
37 - Stock split or consolidation
|
-968,291 vol |
||
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
|
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation
|
-369,183 vol |
92,295 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
|
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation
|
-369,183 vol |
||
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation
|
-968,291 vol |
242,072 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
37 - Stock split or consolidation
|
-968,291 vol |
||
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
|
Rights Phantom Stock Units
37 - Stock split or consolidation
|
-45,440 vol |
11,360 | |
Filed 2016-12-27 Tx date 2016-12-22 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+9,600 vol |
29,600 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
|
Options
37 - Stock split or consolidation
|
$-114,400
-80,000 vol $1.43 each |
20,000 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Holder: JLV Investments, LP (Indirect Ownership)
|
Common Shares
37 - Stock split or consolidation
|
-25,024 vol |
6,256 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Holder: JLD Investments, L.P. (Indirect Ownership)
|
Common Shares
37 - Stock split or consolidation
|
-66,212 vol |
16,553 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
|
Common Shares
37 - Stock split or consolidation
|
-509,966 vol |
127,491 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-968,291 vol |
242,072 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
37 - Stock split or consolidation
|
-3,282 vol |
820 | |
Filed 2016-12-27 Tx date 2016-12-16 |
$NVLN
Novelion Therapeutics Inc. |
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
|
Common Shares
37 - Stock split or consolidation
|
-62,800 vol |
15,700 | |
Filed 2016-12-09 Tx date 2016-11-23 |
$NVLN
Novelion Therapeutics Inc. |
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
35 - Stock dividend
|
+37,000 vol |
37,000 | |
Filed 2016-12-09 Tx date 2012-06-04 |
$NVLN
Novelion Therapeutics Inc. |
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-23 |
$NVLN
Novelion Therapeutics Inc. |
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
35 - Stock dividend
|
+37,000 vol |
37,000 | |
Filed 2016-12-09 Tx date 2012-06-04 |
$NVLN
Novelion Therapeutics Inc. |
Thomas, Jr, John C.
4 - Director of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+99,483 vol |
99,483 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Szela, Mary
4 - Director of Issuer, 5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+9,115 vol |
9,115 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+2,963 vol |
2,963 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Smith, Sandford
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-23 |
$NVLN
Novelion Therapeutics Inc. |
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
35 - Stock dividend
|
+37,000 vol |
37,000 | |
Filed 2016-12-09 Tx date 2012-06-04 |
$NVLN
Novelion Therapeutics Inc. |
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-23 |
$NVLN
Novelion Therapeutics Inc. |
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
35 - Stock dividend
|
+37,000 vol |
37,000 | |
Filed 2016-12-09 Tx date 2012-06-04 |
$NVLN
Novelion Therapeutics Inc. |
Sabba, Stephen
4 - Director of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+35,896 vol |
35,896 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+8,204 vol |
8,204 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Warrants Fully Paid Warrant
16 - Acquisition or disposition under a prospectus exemption
|
+2,840,909 vol |
2,840,909 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Warrants Fully Paid Warrant
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Warrants DOJ/SEC Matter Warrant
16 - Acquisition or disposition under a prospectus exemption
|
+2,840,909 vol |
8,110,740 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Warrants DOJ/SEC Matter Warrant
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-23 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Warrants DOJ/SEC Matter Warrant
35 - Stock dividend
|
+5,269,831 vol |
5,269,831 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Warrants Class Action Lawsuit Warrant
16 - Acquisition or disposition under a prospectus exemption
|
+2,840,909 vol |
8,110,740 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Warrants Class Action Lawsuit Warrant
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-23 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Warrants Class Action Lawsuit Warrant
35 - Stock dividend
|
+5,269,831 vol |
5,269,831 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+4,472,939 vol |
9,742,770 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Kotler, Kevin
3 - 10% Security Holder of Issuer, 4 - Director of Issuer
Holder: Broadfin Health Care Master Fund, Ltd. (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
5,269,831 | ||
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+7,486 vol |
24,012 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+5,230 vol |
16,526 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+2,564 vol |
11,296 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+1,777 vol |
8,732 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+3,589 vol |
6,955 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+3,366 vol |
3,366 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+1,747 vol |
1,747 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Harshbarger, Benjamin
5 - Senior Officer of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-23 |
$NVLN
Novelion Therapeutics Inc. |
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
35 - Stock dividend
|
+78,500 vol |
78,500 | |
Filed 2016-12-09 Tx date 2012-06-04 |
$NVLN
Novelion Therapeutics Inc. |
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-23 |
$NVLN
Novelion Therapeutics Inc. |
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
35 - Stock dividend
|
+78,500 vol |
78,500 | |
Filed 2016-12-09 Tx date 2012-06-04 |
$NVLN
Novelion Therapeutics Inc. |
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-12-06 |
$NVLN
Novelion Therapeutics Inc. |
Cox, Geoffrey F.
4 - Director of Issuer
Direct Ownership
|
Options
50 - Grant of options
|
+50,000 vol |
390,000 | |
Filed 2016-12-09 Tx date 2016-12-06 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
56 - Grant of rights
|
+75,000 vol |
75,000 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Options
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+26,665 vol |
26,665 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Options
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+4,102 vol |
4,102 | |
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Buono, Linda
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Healthcare Master Fund, Ltd.
3 - 10% Security Holder of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
9,742,770 | ||
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Broadfin Capital, LLC
3 - 10% Security Holder of Issuer
Holder: Broadfin Healthcare Master Fund, Ltd. (Control or Direction)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
9,742,770 | ||
Filed 2016-12-09 Tx date 2016-11-23 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
|
Warrants DOJ/SEC Matter Warrant
35 - Stock dividend
|
+461,478 vol |
461,478 | |
Filed 2016-12-09 Tx date 2012-06-04 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
|
Warrants DOJ/SEC Matter Warrant
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
16 - Acquisition or disposition under a prospectus exemption
|
+1,136,363 vol |
1,210,363 | |
Filed 2016-12-09 Tx date 2016-11-23 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
35 - Stock dividend
|
+74,000 vol |
74,000 | |
Filed 2016-12-09 Tx date 2016-11-23 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
|
Warrants Class Action Lawsuit Warrant
35 - Stock dividend
|
+461,478 vol |
461,478 | |
Filed 2016-12-09 Tx date 2012-06-04 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
|
Warrants Class Action Lawsuit Warrant
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
16 - Acquisition or disposition under a prospectus exemption
|
+1,136,363 vol |
1,210,363 | |
Filed 2016-12-09 Tx date 2016-11-23 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
35 - Stock dividend
|
+74,000 vol |
74,000 | |
Filed 2016-12-09 Tx date 2012-06-04 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
|
Warrants Class Action Lawsuit Warrant
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Louis, Roger
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-09 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Chan, Barbara
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-08 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
VanLent, Anne
4 - Director of Issuer
Direct Ownership
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+4,102 vol |
4,102 | |
Filed 2016-12-08 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
VanLent, Anne
4 - Director of Issuer
Direct Ownership
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-08 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Perry, Gregory
5 - Senior Officer of Issuer
Direct Ownership
|
Restricted Stock Unit
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-08 Tx date 2012-06-04 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
|
Warrants DOJ/SEC Matter Warrant
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-02 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Holder: JLV Investments, LP (Indirect Ownership)
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+31,280 vol |
31,280 | |
Filed 2016-12-02 Tx date 2012-06-04 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Holder: JLV Investments, LP (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-02 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Holder: JLD Investments, L.P. (Indirect Ownership)
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+82,765 vol |
82,765 | |
Filed 2016-12-02 Tx date 2012-06-04 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Holder: JLD Investments, L.P. (Indirect Ownership)
|
Common Shares
00 - Opening Balance-Initial SEDI Report
|
|||
Filed 2016-12-02 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Holder: JALAA Equities, LP (Indirect Ownership)
|
Common Shares
22 - Acquisition or disposition pursuant to a take-over bid, merger or acquisition
|
+175,979 vol |
637,457 | |
Filed 2016-12-02 Tx date 2016-11-29 |
$NVLN
Novelion Therapeutics Inc. |
Aryeh, Jason
4 - Director of Issuer
Direct Ownership
|
Common Shares
16 - Acquisition or disposition under a prospectus exemption
|
$1,999,998
+1,136,363 vol $1.76 each |
1,210,363 |